rituximab
Showing 1 - 25 of 1,111
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)
Recruiting
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Rituximab
- Zanubrutinib
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2022
Rituximab in Children With Blood Diseases
Not yet recruiting
- Rituximab
- +2 more
- Rituximab
- Rituximab (once a week)
- (no location specified)
Apr 8, 2022
Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +3 more
- Laboratory Biomarker Analysis
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 26, 2022
Splenic Marginal Zone Lymphoma Trial in Worldwide (Rituximab, Zanubrutinib)
Not yet recruiting
- Splenic Marginal Zone Lymphoma
- Rituximab
- Zanubrutinib
-
Aarhus, Denmark
- +4 more
Feb 17, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +13 more
- Polatuzumab Vedotin
- +3 more
-
Scottsdale, Arizona
- +11 more
Aug 23, 2022
Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, DLBCL Trial in Kampala (Rituximab and Hyaluronidase Human,
Recruiting
- Burkitt Lymphoma
- +2 more
- Rituximab and Hyaluronidase Human
- +8 more
-
Kampala, UgandaUCI-Fred Hutch Cancer Centre
Mar 9, 2022
Prognostic Model of Rituximab in the Treatment of MN
Not yet recruiting
- Idiopathic Membranous Nephropathy
- Rituximab
- (no location specified)
Dec 28, 2022
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular
Recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- +19 more
- CD47 Antagonist ALX148
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma
Not yet recruiting
- Double-Expressor Lymphoma
- +3 more
- Cyclophosphamide
- +6 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 27, 2022
Pharmacological Action Trial (Rituximab, Dexamethasone)
Not yet recruiting
- Pharmacological Action
- Rituximab
- Dexamethasone
- (no location specified)
Sep 22, 2022
Nephrotic Syndrome in Children, Rituximab Trial in Hangzhou (Rituximab, Steroid)
Not yet recruiting
- Nephrotic Syndrome in Children
- Rituximab
- Rituximab
- Steroid
-
Hangzhou, Zhejiang, ChinaChildren's Hospital, Zhejiang University School of Medicine
Feb 9, 2023
Idiopathic Membranous Nephropathy Trial (Rituximab, Cyclophosphamide)
Not yet recruiting
- Idiopathic Membranous Nephropathy
- Rituximab
- Cyclophosphamide
- (no location specified)
Aug 22, 2022
CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)
Active, not recruiting
- CCND1 Positive
- +6 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 11, 2022
Refractory Myasthenia Gravis, Rituximab Trial in Guangzhou (Rituximab)
Recruiting
- Refractory Myasthenia Gravis
- Rituximab
- Rituximab
-
Guangzhou, ChinaFirst Affiliated Hospital, Sun Yat-Sen University
Apr 26, 2022
Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)
Not yet recruiting
- Non-Hodgkin Lymphoma
- Tafasitamab
- +3 more
-
Cologne, GermanyUniversity of Cologne
Oct 14, 2022
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Dasatinib
- +4 more
-
Portland, OregonOHSU Knight Cancer Institute
Apr 4, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial (Nemtabrutinib, Fludarabine, Cyclophosphamide)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Leukemia
- Nemtabrutinib
- +7 more
- (no location specified)
Nov 30, 2022
Schizophrenia Spectrum and Other Psychotic Disorders Trial in Örebro (Rituximab)
Not yet recruiting
- Schizophrenia Spectrum and Other Psychotic Disorders
- Rituximab
-
Örebro, SwedenÖrebro university hospital
Nov 21, 2022
APS Secondary to SLE
Recruiting
- Antiphospholipid Syndrome
- Telitacicept
- +5 more
-
Jinan, Shandong, ChinaQilu Hospital
Nov 30, 2022
Idiopathic Membranous Nephropathy Trial in Beijing (Rituximab, Modified Ponticelli regimen)
Recruiting
- Idiopathic Membranous Nephropathy
- Rituximab
- Modified Ponticelli regimen
-
Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Mar 23, 2023
Steroid-Dependent Nephrotic Syndrome Trial in Kolkata (Rituximab, Mycophenolate Mofetil)
Active, not recruiting
- Steroid-Dependent Nephrotic Syndrome
- Rituximab
- Mycophenolate Mofetil
-
Kolkata, West Bengal, IndiaNilratan Sircar Medical College and Hospital
Apr 6, 2022
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial
Active, not recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +9 more
- Ibrutinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Feb 3, 2022
Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult Trial in Boston (Epcoritamab, Rituximab)
Not yet recruiting
- Follicular Lymphoma
- Low Grade Non-Hodgkin's Lymphoma, Adult
- Epcoritamab
- Rituximab
-
Boston, MassachusettsDana-Farber Cancer Institute
Mar 13, 2023
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Trial in Seattle (procedure, drug, biological)
Not yet recruiting
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Bone Marrow Aspiration and Biopsy
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022